Published in J Chemother on December 01, 1994
Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol (2008) 1.27
Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol (2007) 3.26
Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J (1999) 2.61
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology (2001) 2.53
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Effect of a single, oral, high-dose vitamin D supplementation on endothelial function in patients with peripheral arterial disease: a randomised controlled pilot study. Eur J Vasc Endovasc Surg (2012) 2.12
The influence of a prolonged sitting position on the biochemical markers of coagulation activation in healthy subjects: evidence of reduced thrombin generation. J Thromb Haemost (2003) 1.96
Radiofrequency thermal ablation of 69 lung neoplasms. J Chemother (2004) 1.58
Genes from mycoparasitic fungi as a source for improving plant resistance to fungal pathogens. Proc Natl Acad Sci U S A (1998) 1.50
Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol (1998) 1.47
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast (2010) 1.47
Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA. J Thromb Haemost (2009) 1.41
Standard vs. point-of-care measurement of fibrinogen: potential impact on clinical decisions. Minerva Anestesiol (2012) 1.40
FK 506 as a growth control factor. Transplant Proc (1990) 1.36
Paradoxes in longevity: sequence analysis of mtDNA haplogroup J in centenarians. Eur J Hum Genet (2001) 1.36
Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods (1998) 1.36
Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol (2006) 1.33
Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol (2001) 1.32
Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. Hepatology (1991) 1.30
Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J Clin Microbiol (2006) 1.29
Canine total orthotopic small bowel transplantation under FK 506. Transplant Proc (1991) 1.29
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol (2007) 1.28
Gene/longevity association studies at four autosomal loci (REN, THO, PARP, SOD2). Eur J Hum Genet (1999) 1.25
Age-related changes of the 3'APOB-VNTR genotype pool in ageing cohorts. Ann Hum Genet (1998) 1.18
Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology (2000) 1.17
The role of Aurora-A inhibitors in cancer therapy. Ann Oncol (2007) 1.16
Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc (1990) 1.14
Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol (2001) 1.09
In situ characterization by monoclonal antibodies of the mononuclear cell infiltrate in chronic active hepatitis. Gastroenterology (1983) 1.06
Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology (1992) 1.06
Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer Treat Rev (2010) 1.05
Inhibition of liver, kidney, and intestine regeneration by rapamycin. Transplantation (1992) 1.00
Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. J Hepatol (1996) 1.00
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer (2011) 1.00
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer (2011) 0.98
Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev (2010) 0.96
In situ characterization of the cell-surface antigens of the mononuclear cell infiltrate and bile duct epithelium in primary biliary cirrhosis. Clin Immunol Immunopathol (1986) 0.95
New molecular targets in bone metastases. Cancer Treat Rev (2010) 0.95
Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol (2006) 0.94
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Ann Oncol (2006) 0.94
High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. J Clin Virol (2011) 0.92
Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol (2000) 0.92
Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon. J Med Virol (1997) 0.92
Treatment of advanced non-small cell lung cancer. Ann Oncol (2006) 0.91
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression. Ann Oncol (2006) 0.91
Inherited variability of the mitochondrial genome and successful aging in humans. Ann N Y Acad Sci (2000) 0.91
Effect on the canine Eck fistula liver of intraportal TGF-beta alone or with hepatic growth factors. Hepatology (1992) 0.89
Does a retrograde response in human aging and longevity exist? Exp Gerontol (2000) 0.89
Renal adaptation to dietary sodium restriction in moderate renal failure resulting from chronic glomerular disease. J Am Soc Nephrol (1996) 0.89
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol (2007) 0.89
A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat (1996) 0.89
Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer. Ann Oncol (2007) 0.88
The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B virus infection. J Hepatol (1999) 0.87
Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Ann Oncol (2007) 0.86
Trends in colorectal day case surgery in NHS Trusts between 1998 and 2005. Colorectal Dis (2008) 0.86
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol (2006) 0.86
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer (2005) 0.86
Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Preliminary results. Dig Dis Sci (1994) 0.86
Lactobacillus plantarum reduces infection of pancreatic necrosis in experimental acute pancreatitis. Dig Surg (2001) 0.86
A cohort study of results following elective colonic and rectal resection within an enhanced recovery programme. Colorectal Dis (2009) 0.86
Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology (1999) 0.86
Molecular characterization of a bean alpha-amylase inhibitor that inhibits the alpha-amylase of the mexican bean weevil Zabrotes subfasciatus. Planta (1997) 0.86
Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res (2000) 0.86
Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev (2010) 0.85
[Renal peripelvic multicystic lymphangiectasia: is echographic diagnosis possible?]. Arch Ital Urol Androl (1996) 0.85
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol (2006) 0.85
Interactions between hepatitis B virus and polymeric human serum albumin. II. Development of syngeneic monoclonal anti-anti-idiotypes which mimic hepatitis B surface antigen in the induction of immune responsiveness. Eur J Immunol (1987) 0.84
Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am J Transplant (2011) 0.84
Hepatitis B virus transcripts and surface antigen in human peripheral blood lymphocytes. J Med Virol (1990) 0.84
The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. Transplant Proc (1991) 0.84
Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model. J Hepatol (1998) 0.83
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol (2010) 0.83
The cobas p 630 instrument: a dedicated pre-analytic solution to optimize COBAS® AmpliPrep/COBAS® TaqMan® system workflow and turn-around-time. J Virol Methods (2012) 0.83
Development of a nested PCR assay for detection of feline infectious peritonitis virus in clinical specimens. J Clin Microbiol (1997) 0.83
Emotional expression and coping style in female breast cancer. Ann Oncol (2007) 0.83
HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr (1993) 0.83
Maintenance therapy in colon cancer. Cancer Treat Rev (2010) 0.83
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Anticancer Drugs (1997) 0.83
Quantitation of hepatitis C virus in liver and peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection. J Med Virol (1998) 0.82
Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus. Ann Oncol (2007) 0.81
[On the Marinesco-Sjogren syndrome. (Observations on 2 familial cases)]. G Psichiatr Neuropatol (1965) 0.81
IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. J Med Virol (1998) 0.81
Administration of hepatic stimulatory substance alone or with other liver growth factors does not ameliorate acetaminophen-induced liver failure. Hepatology (1993) 0.80
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. Eur J Cancer (2011) 0.80
Analysis of extended genomic rearrangements in oncological research. Ann Oncol (2007) 0.80
Detection of the hepatitis B virus major pre-core mutation by the amplification refractory mutation system technique. Res Virol (1993) 0.80
Stability of hepatitis C virus RNA in serum from samples collected in a closed-tube system for serum separation and transport, as measured by a quantitative competitive PCR assay. J Viral Hepat (1996) 0.80
Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients. Blood (1990) 0.79
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). Ann Oncol (2007) 0.79
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Ann Oncol (2000) 0.79
ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin. Am J Transplant (2009) 0.78
Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol (2006) 0.78